Zacks Research Comments on OPKO Health FY2027 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Research analysts at Zacks Research issued their FY2027 earnings per share estimates for OPKO Health in a note issued to investors on Thursday, March 20th. Zacks Research analyst R. Department forecasts that the biotechnology company will post earnings per share of ($0.09) for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

OPKO Health (NASDAQ:OPK) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million.

OPK has been the topic of several other reports. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Wednesday, March 19th. StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th.

OPKO Health Stock Performance

Shares of OPK opened at $1.80 on Monday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -9.47 and a beta of 1.70. OPKO Health has a 12 month low of $0.99 and a 12 month high of $2.04. The firm has a fifty day simple moving average of $1.66 and a 200 day simple moving average of $1.58. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

Institutional Investors Weigh In On OPKO Health

Large investors have recently added to or reduced their stakes in the business. Intech Investment Management LLC bought a new position in OPKO Health during the third quarter worth $190,000. FMR LLC lifted its stake in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after buying an additional 217,450 shares during the last quarter. Rubric Capital Management LP boosted its holdings in shares of OPKO Health by 9.6% during the 3rd quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after buying an additional 4,284,336 shares during the period. Finally, Verition Fund Management LLC acquired a new position in OPKO Health in the 3rd quarter valued at about $201,000. Institutional investors own 64.63% of the company’s stock.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock in a transaction dated Friday, January 17th. The stock was bought at an average cost of $1.47 per share, for a total transaction of $220,500.00. Following the purchase, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at $313,384,121.19. The trade was a 0.07 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have bought 964,971 shares of company stock valued at $1,493,692. 47.26% of the stock is currently owned by corporate insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.